57901dc3-9b2f-4271-8dd9-8fc0121d6971
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66.6666666666667
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.620
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- DNA_REPAIR+0.360
- MYC_TARGETS_V1+0.360
- FATTY_ACID_METABOLISM+0.350
- XENOBIOTIC_METABOLISM+0.270
- ALLOGRAFT_REJECTION+0.250
- MTORC1_SIGNALING+0.250
- MYC_TARGETS_V2+0.250
- GLYCOLYSIS+0.240
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.520
- WNT_BETA_CATENIN_SIGNALING-0.500
- MITOTIC_SPINDLE-0.450
- APICAL_SURFACE-0.350
- UV_RESPONSE_DN-0.330
- MYOGENESIS-0.280
- ANGIOGENESIS-0.270
- G2M_CHECKPOINT-0.270
- KRAS_SIGNALING_DN-0.270
- APICAL_JUNCTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR27320676 | — | — | 0.880 |
| 2 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.875 |
| 3 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.858 |
| 4 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.854 |
| 5 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.815 |
| 6 | TCGA-05-5428-01A-01R-1628-07 | — | cohortA1 | 0.804 |
| 7 | TCGA-38-4631-01A-01R-1755-07 | — | cohortA4 | 0.803 |
| 8 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.799 |
| 9 | 10013d81-e167-4aa0-b548-5bb359ed403a | — | — | 0.797 |
| 10 | SRR9879275 | — | cohortA1 | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.620 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |